USP Medicine Supply Map Impact Analysis: Aurobindo partially halts production at Eugia's Unit-III

On February 5, Eugia, a subsidiary of Aurobindo Pharma, announced a partial halt in production of 56 national drug codes (NDCs) at its Unit-III facility in Hyderabad, India, due to observations made during an FDA investigation.

USP assessed the potential impact of this production halt on drug availability using USP's Medicine Supply Map, a robust database of over 250 million data points, including sources of drug ingredients, drug products, drug shortage predictions and manufacturers information. By mapping out the production landscape, we identified that Eugia produces 64 more than 60 prescription drug products, with 27 drug products having greater than 15 percent market share, including injectables. Notably, six of these products have greater than 50 percent market share and one of which is currently experiencing a shortage. Eugia stated that it aims to resume production promptly and assures that products meet quality standards mandated for patient safety and regulatory compliance.

This case underscores the importance of using tools like USP’s Medicine Supply Map for proactive monitoring and predictive analysis in mitigating supply chain disruptions and ensuring uninterrupted access to quality medicines for patients.

About USP Medicine Supply Map

The USP Medicine Supply Map calculates the vulnerability scores and market shares of drug products and APIs. Based on this data, USP can pinpoint drugs at heightened shortage risk in the mid-term (> 3 months), make recommendations to avoid drug shortages, and identify drugs that are not at significantly higher risk of drug shortage where pre-emptive action is not currently needed.

For additional information, please contact us at to learn more.